FDA approves Rituxan as first targeted B-cell therapy for treatment of rheumatoid arthritisGenentech, Inc. and Biogen Idec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in com ...GenentechInc. and Biogen Idecfollowing Priority Review
Learn about RITUXAN® (rituximab) treatment for rheumatoid arthritis (RA) patients including efficacy, safety, MOA and dosing. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
Learn about RITUXAN® (rituximab) treatment for rheumatoid arthritis (RA) patients including efficacy, safety, MOA and dosing. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
Rituxan, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapiesRituxan, in combination with glucocorticoids, is indicated for the ...
Adults with Rheumatoid arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well en...
Adults with Rheumatoid arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well en...
Adults with Rheumatoid arthritis (RA):with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well enou...
Rheumatoid arthritis (RA)in adults, in combination with methotrexate, to reduce signs and symptoms of moderate to severely active RA after an inadequate response to treatment with a Tumor Necrosis Factor (TNF) antagonist Granulomatosis with Polyangiitis (GPA, Wegener's granulomatosis)and Microscopic Pol...
Rituximab (Rituxan) is a medication prescribed for the treatment of non-Hodgkin's B-cell lymphomas, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis. Rituxan is combined with methotrexate (Trexall) to treat rheumatoid arthritis. Side effects, drug interactions, ...
RITUXAN, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL. 1.3 Rheumatoid Arthritis (RA) RITUXAN, in combination with methotrexate, is indicated for the treatment of adult patien...